Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality
Purpose : To determine the clinical outcome, prognostic factors, and effect of adding combination chemotherapy to radiation therapy on disease control and survival in early stage nasal natural killer (NK)/T-cell lymphoma. Methods and Materials : A retrospective “intent to treat” analysis was carried...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2002-09, Vol.54 (1), p.182-190 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 190 |
|---|---|
| container_issue | 1 |
| container_start_page | 182 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 54 |
| creator | Cheung, Michael M.C Chan, John K.C Lau, Wai-hon Ngan, Roger K.C Foo, William W.L |
| description | Purpose
: To determine the clinical outcome, prognostic factors, and effect of adding combination chemotherapy to radiation therapy on disease control and survival in early stage nasal natural killer (NK)/T-cell lymphoma.
Methods and Materials
: A retrospective “intent to treat” analysis was carried out on 79 patients treated consecutively with curative intent between 1977 and June 2001. They all had early stage (Ann Arbor Stage I
E: 63, II
E:16) nasal NK/T-cell lymphoma. Sixty-one were planned for combined modality treatment (CMT); radiotherapy alone (RT) was intended for 18. Three to 6 cycles of anthracycline-containing regimens were aimed at for patients intended for CMT. Patients selected for RT were generally older or treated during the earlier part of the study period.
Results
: The overall complete response (CR) rate was 68.4% (54/79), of whom 44.4% (24/54) relapsed after 54.9 months median follow-up of the survivors. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 35.5% and 37.9%, respectively. On multivariate analysis, good performance status (Eastern Cooperative Oncology Group [ECOG] |
| doi_str_mv | 10.1016/S0360-3016(02)02916-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71995475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301602029164</els_id><sourcerecordid>71995475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-ad07a7ca437cb4223caa0c46a43d1d38a8441c5ef6610f82aea47a2434d3962f3</originalsourceid><addsrcrecordid>eNqFkEtvFDEMgCMEokvhJ4ByAYHUoXnNiwtCVXmICg4UiVvkOk4bNDPZJlmk_fdkuyt65OTI_hzbH2PPpXgrhexOfwjdiUbX52uh3gg1yq4xD9hKDv3Y6Lb99ZCt_iFH7EnOv4UQUvbmMTuSSg5qHMWKrc8hTVueC1wTXyDDxL99Pb1skKaJT9t5fRNneMdxCkvAWoybgnGmE75O8XqJuQTkHrDElE84LI6XG-LkPWHh0fOSCMpMS-FzdDCFsn3KHnmYMj07xGP28-P55dnn5uL7py9nHy4aNEaXBpzooUcwuscro5RGAIGmqwknnR5gMEZiS77rpPCDAgLTgzLaOD12yutj9mr_b130dkO52Dnk3VWwUNxk28txbE3fVrDdg5hizom8XacwQ9paKexOtb1TbXcerVD2TrU1te_FYcDmaiZ333VwW4GXBwByVecTLBjyPaeHwWg9Vu79nqOq40-gZDMGWpBcSFWjdTH8Z5W_foubbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71995475</pqid></control><display><type>article</type><title>Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cheung, Michael M.C ; Chan, John K.C ; Lau, Wai-hon ; Ngan, Roger K.C ; Foo, William W.L</creator><creatorcontrib>Cheung, Michael M.C ; Chan, John K.C ; Lau, Wai-hon ; Ngan, Roger K.C ; Foo, William W.L</creatorcontrib><description>Purpose
: To determine the clinical outcome, prognostic factors, and effect of adding combination chemotherapy to radiation therapy on disease control and survival in early stage nasal natural killer (NK)/T-cell lymphoma.
Methods and Materials
: A retrospective “intent to treat” analysis was carried out on 79 patients treated consecutively with curative intent between 1977 and June 2001. They all had early stage (Ann Arbor Stage I
E: 63, II
E:16) nasal NK/T-cell lymphoma. Sixty-one were planned for combined modality treatment (CMT); radiotherapy alone (RT) was intended for 18. Three to 6 cycles of anthracycline-containing regimens were aimed at for patients intended for CMT. Patients selected for RT were generally older or treated during the earlier part of the study period.
Results
: The overall complete response (CR) rate was 68.4% (54/79), of whom 44.4% (24/54) relapsed after 54.9 months median follow-up of the survivors. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 35.5% and 37.9%, respectively. On multivariate analysis, good performance status (Eastern Cooperative Oncology Group [ECOG] <2) was shown to be a significant favorable factor for DFS (
p = 0.011), whereas good performance status (ECOG <2) and Ann Arbor Stage I
E disease were shown to be significant favorable factors for OS (
p = 0.001 and
p = 0.013, respectively). The type of intended treatment was not a significant factor for DFS (5-year DFS CMT vs. RT = 35.8% vs. 30.5%,
p = 0.795) or OS (5-year OS CMT vs. RT = 40.3% vs. 29.8%,
p = 0.693) though only 2 of the 16 Stage II
E patients were intended for RT alone. Resistance to treatment, especially to chemotherapy, was common. Of 61 patients intended to be given CMT, 31 showed disease progression while receiving chemotherapy, of whom 17 progressed locoregionally. Nine of the latter group were rendered CR by salvage radiotherapy.
Conclusions
: The overall outcome in early stage nasal NK/T-cell lymphoma is poor. Performance status and Ann Arbor stage are significant factors influencing DFS and OS. The addition of anthracycline-containing chemotherapy to radiotherapy does not appear to confer any survival benefit in Stage I
E patients. Therefore, radiation therapy remains the mainstay of treatment for this lymphoma type.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/S0360-3016(02)02916-4</identifier><identifier>PMID: 12182990</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Combined Modality Therapy ; Diseases of the upper aerodigestive tract ; Ent and stomatology ; Female ; Humans ; Killer Cells, Natural ; Lymphoma, T-Cell - therapy ; Male ; Medical sciences ; Middle Aged ; Nasal lymphoma ; Nose Neoplasms - therapy ; Otorhinolaryngology. Stomatology ; Prognosis ; Prognostic factors ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Retrospective Studies ; T-cell lymphoma ; Treatment ; Treatment Failure ; Tumors ; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><ispartof>International journal of radiation oncology, biology, physics, 2002-09, Vol.54 (1), p.182-190</ispartof><rights>2002 Elsevier Science Inc.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-ad07a7ca437cb4223caa0c46a43d1d38a8441c5ef6610f82aea47a2434d3962f3</citedby><cites>FETCH-LOGICAL-c443t-ad07a7ca437cb4223caa0c46a43d1d38a8441c5ef6610f82aea47a2434d3962f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301602029164$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13884339$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12182990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheung, Michael M.C</creatorcontrib><creatorcontrib>Chan, John K.C</creatorcontrib><creatorcontrib>Lau, Wai-hon</creatorcontrib><creatorcontrib>Ngan, Roger K.C</creatorcontrib><creatorcontrib>Foo, William W.L</creatorcontrib><title>Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose
: To determine the clinical outcome, prognostic factors, and effect of adding combination chemotherapy to radiation therapy on disease control and survival in early stage nasal natural killer (NK)/T-cell lymphoma.
Methods and Materials
: A retrospective “intent to treat” analysis was carried out on 79 patients treated consecutively with curative intent between 1977 and June 2001. They all had early stage (Ann Arbor Stage I
E: 63, II
E:16) nasal NK/T-cell lymphoma. Sixty-one were planned for combined modality treatment (CMT); radiotherapy alone (RT) was intended for 18. Three to 6 cycles of anthracycline-containing regimens were aimed at for patients intended for CMT. Patients selected for RT were generally older or treated during the earlier part of the study period.
Results
: The overall complete response (CR) rate was 68.4% (54/79), of whom 44.4% (24/54) relapsed after 54.9 months median follow-up of the survivors. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 35.5% and 37.9%, respectively. On multivariate analysis, good performance status (Eastern Cooperative Oncology Group [ECOG] <2) was shown to be a significant favorable factor for DFS (
p = 0.011), whereas good performance status (ECOG <2) and Ann Arbor Stage I
E disease were shown to be significant favorable factors for OS (
p = 0.001 and
p = 0.013, respectively). The type of intended treatment was not a significant factor for DFS (5-year DFS CMT vs. RT = 35.8% vs. 30.5%,
p = 0.795) or OS (5-year OS CMT vs. RT = 40.3% vs. 29.8%,
p = 0.693) though only 2 of the 16 Stage II
E patients were intended for RT alone. Resistance to treatment, especially to chemotherapy, was common. Of 61 patients intended to be given CMT, 31 showed disease progression while receiving chemotherapy, of whom 17 progressed locoregionally. Nine of the latter group were rendered CR by salvage radiotherapy.
Conclusions
: The overall outcome in early stage nasal NK/T-cell lymphoma is poor. Performance status and Ann Arbor stage are significant factors influencing DFS and OS. The addition of anthracycline-containing chemotherapy to radiotherapy does not appear to confer any survival benefit in Stage I
E patients. Therefore, radiation therapy remains the mainstay of treatment for this lymphoma type.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Combined Modality Therapy</subject><subject>Diseases of the upper aerodigestive tract</subject><subject>Ent and stomatology</subject><subject>Female</subject><subject>Humans</subject><subject>Killer Cells, Natural</subject><subject>Lymphoma, T-Cell - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nasal lymphoma</subject><subject>Nose Neoplasms - therapy</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Prognosis</subject><subject>Prognostic factors</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Retrospective Studies</subject><subject>T-cell lymphoma</subject><subject>Treatment</subject><subject>Treatment Failure</subject><subject>Tumors</subject><subject>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtvFDEMgCMEokvhJ4ByAYHUoXnNiwtCVXmICg4UiVvkOk4bNDPZJlmk_fdkuyt65OTI_hzbH2PPpXgrhexOfwjdiUbX52uh3gg1yq4xD9hKDv3Y6Lb99ZCt_iFH7EnOv4UQUvbmMTuSSg5qHMWKrc8hTVueC1wTXyDDxL99Pb1skKaJT9t5fRNneMdxCkvAWoybgnGmE75O8XqJuQTkHrDElE84LI6XG-LkPWHh0fOSCMpMS-FzdDCFsn3KHnmYMj07xGP28-P55dnn5uL7py9nHy4aNEaXBpzooUcwuscro5RGAIGmqwknnR5gMEZiS77rpPCDAgLTgzLaOD12yutj9mr_b130dkO52Dnk3VWwUNxk28txbE3fVrDdg5hizom8XacwQ9paKexOtb1TbXcerVD2TrU1te_FYcDmaiZ333VwW4GXBwByVecTLBjyPaeHwWg9Vu79nqOq40-gZDMGWpBcSFWjdTH8Z5W_foubbQ</recordid><startdate>20020901</startdate><enddate>20020901</enddate><creator>Cheung, Michael M.C</creator><creator>Chan, John K.C</creator><creator>Lau, Wai-hon</creator><creator>Ngan, Roger K.C</creator><creator>Foo, William W.L</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020901</creationdate><title>Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality</title><author>Cheung, Michael M.C ; Chan, John K.C ; Lau, Wai-hon ; Ngan, Roger K.C ; Foo, William W.L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-ad07a7ca437cb4223caa0c46a43d1d38a8441c5ef6610f82aea47a2434d3962f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Combined Modality Therapy</topic><topic>Diseases of the upper aerodigestive tract</topic><topic>Ent and stomatology</topic><topic>Female</topic><topic>Humans</topic><topic>Killer Cells, Natural</topic><topic>Lymphoma, T-Cell - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nasal lymphoma</topic><topic>Nose Neoplasms - therapy</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Prognosis</topic><topic>Prognostic factors</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Retrospective Studies</topic><topic>T-cell lymphoma</topic><topic>Treatment</topic><topic>Treatment Failure</topic><topic>Tumors</topic><topic>Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheung, Michael M.C</creatorcontrib><creatorcontrib>Chan, John K.C</creatorcontrib><creatorcontrib>Lau, Wai-hon</creatorcontrib><creatorcontrib>Ngan, Roger K.C</creatorcontrib><creatorcontrib>Foo, William W.L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheung, Michael M.C</au><au>Chan, John K.C</au><au>Lau, Wai-hon</au><au>Ngan, Roger K.C</au><au>Foo, William W.L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2002-09-01</date><risdate>2002</risdate><volume>54</volume><issue>1</issue><spage>182</spage><epage>190</epage><pages>182-190</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>Purpose
: To determine the clinical outcome, prognostic factors, and effect of adding combination chemotherapy to radiation therapy on disease control and survival in early stage nasal natural killer (NK)/T-cell lymphoma.
Methods and Materials
: A retrospective “intent to treat” analysis was carried out on 79 patients treated consecutively with curative intent between 1977 and June 2001. They all had early stage (Ann Arbor Stage I
E: 63, II
E:16) nasal NK/T-cell lymphoma. Sixty-one were planned for combined modality treatment (CMT); radiotherapy alone (RT) was intended for 18. Three to 6 cycles of anthracycline-containing regimens were aimed at for patients intended for CMT. Patients selected for RT were generally older or treated during the earlier part of the study period.
Results
: The overall complete response (CR) rate was 68.4% (54/79), of whom 44.4% (24/54) relapsed after 54.9 months median follow-up of the survivors. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 35.5% and 37.9%, respectively. On multivariate analysis, good performance status (Eastern Cooperative Oncology Group [ECOG] <2) was shown to be a significant favorable factor for DFS (
p = 0.011), whereas good performance status (ECOG <2) and Ann Arbor Stage I
E disease were shown to be significant favorable factors for OS (
p = 0.001 and
p = 0.013, respectively). The type of intended treatment was not a significant factor for DFS (5-year DFS CMT vs. RT = 35.8% vs. 30.5%,
p = 0.795) or OS (5-year OS CMT vs. RT = 40.3% vs. 29.8%,
p = 0.693) though only 2 of the 16 Stage II
E patients were intended for RT alone. Resistance to treatment, especially to chemotherapy, was common. Of 61 patients intended to be given CMT, 31 showed disease progression while receiving chemotherapy, of whom 17 progressed locoregionally. Nine of the latter group were rendered CR by salvage radiotherapy.
Conclusions
: The overall outcome in early stage nasal NK/T-cell lymphoma is poor. Performance status and Ann Arbor stage are significant factors influencing DFS and OS. The addition of anthracycline-containing chemotherapy to radiotherapy does not appear to confer any survival benefit in Stage I
E patients. Therefore, radiation therapy remains the mainstay of treatment for this lymphoma type.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>12182990</pmid><doi>10.1016/S0360-3016(02)02916-4</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2002-09, Vol.54 (1), p.182-190 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71995475 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences Combined Modality Therapy Diseases of the upper aerodigestive tract Ent and stomatology Female Humans Killer Cells, Natural Lymphoma, T-Cell - therapy Male Medical sciences Middle Aged Nasal lymphoma Nose Neoplasms - therapy Otorhinolaryngology. Stomatology Prognosis Prognostic factors Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Retrospective Studies T-cell lymphoma Treatment Treatment Failure Tumors Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology |
| title | Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T19%3A27%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20stage%20nasal%20NK/T-cell%20lymphoma:%20clinical%20outcome,%20prognostic%20factors,%20and%20the%20effect%20of%20treatment%20modality&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Cheung,%20Michael%20M.C&rft.date=2002-09-01&rft.volume=54&rft.issue=1&rft.spage=182&rft.epage=190&rft.pages=182-190&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/S0360-3016(02)02916-4&rft_dat=%3Cproquest_cross%3E71995475%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71995475&rft_id=info:pmid/12182990&rft_els_id=S0360301602029164&rfr_iscdi=true |